← SynDRA
IFOSFAMIDE
SynDRA canonical compound SYN0003205 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PTGS1 |
|---|
| Mechanism of action | DNA alkylating agent |
|---|
| Indication | hemorrhagic cystitis | testicular carcinoma |
|---|
| Disease area | oncology | urology |
|---|
All known targets
- CYP2A6
- CYP2B6
- CYP2C18
- CYP2C19
- CYP2C8
- CYP2C9
- CYP3A4
- CYP3A5
- CYP3A7
- PTGS1
Mechanisms of action (all sources)
Drug classes
- Alkylating Activity
- Alkylating Drug
- Alkylating Agents
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Noxae
ATC classes
Cross-references
Synonyms
- holoxan
- ifomide
- ifosfamid
- ifosfomide
- ifosphamide
- iphosphamide
- isoendoxan
- isofosfamide
- isophosphamide
- mitoxana
- naxamide
- Ifosfamida
- Isocyclophosphamide
- Isophosphamide
- MJF-9325
- NSC-109724
- Z-4942
- Z4942
- Ifex
- Ifsofamide
- Mitoxana
- Cyfos
- Holoxan
- Ifosfamid
- Ifosfamidum
- Ifosphamide
- Iphosphamid
- Iphosphamide
- Isoendoxan
- Isofosfamide
- Isosfamide
- Naxamide
- Ifosfamide Sterile
- Iso-Endoxan
- A 4942
- ASTA Z 4942
- Holoxan 1000
- I-Phosphamide
Reported adverse events
- Myelosuppression
- Hemorrhagic cystitis
- Hemorrhagic cyst
- Nephrotoxicity
- CNS toxicity
- Alopecia
- Constipation
- Dermatitis
- Fanconi syndrome
- Fatigue
- Hypertension
- Hypotension
Look up IFOSFAMIDE in the interactive SynDRA portal →